The American Gastroenterological Association surveyed 180 of its members on biosimilars and biologics.

1. 40%
71%
72%
67%
40% of respondents said they were
very familiar with biosimilars, 51%
said they were only slightly familiar
with biosimilars
72% reported that they were likely
to prescribe biosimilars if/when they
become available in the US, 49%
said they were very likely
71% claimed they were likely to
prescribe an interchangeable
biosimilar, while only 59% would
prescribe a non-interchangeable
one
67% of gastroenterologists
surveyed favor prohibition of
indication extrapolation in approval
of biosimilars for IBD
In response to biosimilar standards, quality, and safety:
biosimilars.us | What Do Gastroenterologists Think?
What Do Gastroenterologists Think?
80% are very concerned about
clinical similarity between the
biosimilar and reference product in
regards to effectiveness and safety
78% of respondents are very
concerned about the
immunogenicity and safety of
biosimilars
55% of the gastroenterologists
surveyed feel pharmacy level
substitution should only be
permitted with notification of
prescriber
35% believe pharmacy level
substitution should be ruled out all
together
When considering the use of a biosimilar:
80% 78%
55% 35%
69% said their reasoning is lack of
experience with biosimilars
65% said more time is needed to
examine the effectiveness of
biosimilars
Out of those who said they were unlikely to prescribe biosimilars:
69% 65%
Source:
Gastro.org,. 'National Survey Reveals Gastroenterologists' Views On Biosimilar Drugs'. N.p., 2015. Web. 17
Aug. 2015.
In late July, the American Gastroenterological Association released findings from a national survey of
gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory
bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra are globally on the
rise.
This survey reveals that many gastroenterologists are concerned about the safety and efficacy of biosimilars
and that some are still unfamiliar with the type of drug itself.